title: Quinolone arthropathy in animals versus children.
abstract: The use of quinolones in children and accumulation of data on the pharmacodynamics of these drugs have been limited and delayed by concern regarding their chondrotoxicity. A comprehensive review of the findings in animals compared with the cumulative published findings in children and adolescents (>7,000 to date) allows the conclusion that such concern is not justified. Prospective controlled studies in children are justifiable in view of a continuing lack of correlation between findings in juvenile animals and those in children and because of the selected therapeutic advantages of the current and newer quinolones.
authors.affiliation: Pfizer, Inc., Groton, Connecticut 06340, USA.
authors.forename: J E
authors.initials: JE
authors.lastname: Burkhardt
authors.forename: J N
authors.initials: JN
authors.lastname: Walterspiel
authors.forename: U B
authors.initials: UB
authors.lastname: Schaad
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000818:Animals; D018771:Arthralgia / Q000139:chemically induced; D002356:Cartilage / Q000187:drug effects; D002648:Child; D006128:Growth; D006801:Humans; D007592:Joint Diseases / Q000139:chemically induced* / Q000503:physiopathology; D015363:Quinolones / Q000009:adverse effects* / Q000494:pharmacology
chemical_list: D015363:Quinolones